{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:02:04Z","timestamp":1784869324035,"version":"3.55.0"},"reference-count":223,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007445","name":"Matthew Larson Foundation for Pediatric Brain Tumors","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R61 NS144359"],"award-info":[{"award-number":["R61 NS144359"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM136577"],"award-info":[{"award-number":["T32 GM136577"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The advent of cancer immunotherapy has led to dramatically improved outcomes in several immunogenic adult cancers. Similar successes have been seen in some pediatric cancers, but only in specific settings. A particular challenge has been the application of immunotherapy approaches to pediatric brain tumors, with early clinical experience showing promise but few durable responses. Key barriers to immunotherapy arise from distinctive features of pediatric brain tumors, including low tumor immunogenicity, an immunosuppressive tumor microenvironment, and impaired effector cell function. Additionally, the application of immunotherapies to the confined space of the CNS must be carefully calibrated to avoid neurological toxicity. Unlike immunogenic adult cancers, many pediatric brain tumors have a paucity of genetic mutations and are driven by epigenetic alterations. Tumor subtypes with the same genetic driver can have markedly different tumor immune microenvironments, illustrating that non-genetic factors contribute to immune dysregulation. Here, we review key features of the tumor immune microenvironments of malignant pediatric brain tumors and consider how these features serve as barriers to successful application of immunotherapy. We evaluate evidence that pharmacologic manipulation of the epigenome can be leveraged to shape the tumor immune microenvironment and consider combinatorial approaches using epigenetic-targeted therapies and immunotherapies to inform future clinical studies of pediatric brain tumors.<\/jats:p>","DOI":"10.3389\/fonc.2026.1857121","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:29Z","timestamp":1784867009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Ashley R.","family":"Tetens","sequence":"first","affiliation":[{"name":"Center for Epigenetics, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Department of Physiology, Pharmacology, and Therapeutics, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn","family":"Craig-Schwartz","sequence":"additional","affiliation":[{"name":"Center for Epigenetics, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler R.","family":"Findlay","sequence":"additional","affiliation":[{"name":"Center for Epigenetics, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Koldobskiy","sequence":"additional","affiliation":[{"name":"Center for Epigenetics, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Department of Physiology, Pharmacology, and Therapeutics, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2017.06.006","article-title":"Engineering challenges for brain tumor immunotherapy","volume":"114","author":"Lyon","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050379","article-title":"Pediatric brain tumours: Lessons from the immune microenvironment","volume":"30","author":"Yao","year":"2023","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1602529","article-title":"Advances and challenges in cancer immunotherapy: mechanisms, clinical applications, and future directions","volume":"16","author":"Vatsavai","year":"2025","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","article-title":"Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas","volume":"35","author":"Krug","year":"2019","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase I trial combining decitabine\/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0070","article-title":"Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos Torres","year":"2024","journal-title":"Nat Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1038\/s41467-024-49595-1","article-title":"Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment","volume":"15","author":"Levine","year":"2024","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npad005","article-title":"Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT)","volume":"10","author":"Tran","year":"2023","journal-title":"Neuro-Oncol Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.343","article-title":"Hot and cold tumors: Immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm (2020)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/28212","article-title":"Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer","volume":"394","author":"Versteege","year":"1998","journal-title":"Nature"},{"key":"B20","article-title":"Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors","volume":"59","author":"Biegel","year":"1999","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ccell.2016.11.003","article-title":"Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors","volume":"30","author":"Torchia","year":"2016","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.02.001","article-title":"Atypical teratoid\/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes","volume":"29","author":"Johann","year":"2016","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz235","article-title":"Molecular subgrouping of atypical teratoid\/rhabdoid tumors-a reinvestigation and current consensus","volume":"22","author":"Ho","year":"2020","journal-title":"Neuro Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1017\/s031716710001533x","article-title":"Immune cell infiltrates in atypical teratoid\/rhabdoid tumors","volume":"39","author":"Lu","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ccell.2019.10.008","article-title":"Clonally expanded T cells reveal immunogenicity of rhabdoid tumors","volume":"36","author":"Leruste","year":"2019","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.celrep.2019.10.013","article-title":"Identification and analyses of extra-cranial and cranial rhabdoid tumor molecular subgroups reveal tumors with cytotoxic T cell infiltration","volume":"29","author":"Chun","year":"2019","journal-title":"Cell Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-019-09981-6","article-title":"PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism","volume":"10","author":"Jain","year":"2019","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz058","article-title":"EZHIP\/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma","volume":"21","author":"H\u00fcbner","year":"2019","journal-title":"Neuro Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02682-x","article-title":"Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology","volume":"147","author":"G\u00f6dicke","year":"2024","journal-title":"Acta Neuropathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03450-2","article-title":"Characterizing the tumor immune microenvironment of ependymomas using targeted gene expression profiles and RNA sequencing","volume":"72","author":"de Koning","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-019-00350-1","article-title":"Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade","volume":"36","author":"Nambirajan","year":"2019","journal-title":"Brain Tumor Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0061","article-title":"Interleukin-6\/STAT3 pathway signaling drives an inflammatory phenotype in group A ependymoma","volume":"3","author":"Griesinger","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107585","article-title":"Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma","volume":"26","author":"Griesinger","year":"2023","journal-title":"iScience"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1066","article-title":"ZFTA-RELA dictates oncogenic transcriptional programs to drive aggressive supratentorial ependymoma","volume":"11","author":"Arabzade","year":"2021","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40478-021-01135-4","article-title":"C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation","volume":"9","author":"Ozawa","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26960","article-title":"Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy","volume":"65","author":"Witt","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3811","article-title":"Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma","volume":"14","author":"Jones","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1038\/s41467-024-52096-w","article-title":"Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function","volume":"15","author":"Andrade","year":"2024","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/neuonc\/noy145","article-title":"Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy","volume":"21","author":"Lieberman","year":"2019","journal-title":"Neuro Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154229","article-title":"H3.3-G34 mutations impair DNA repair and promote cGAS\/STING-mediated immune responses in pediatric high-grade glioma models","volume":"132","author":"Haase","year":"2022","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2023.06.13.544658","DOI":"10.1101\/2023.06.13.544658","article-title":"H3.3-G34R mutation-mediated epigenetic reprogramming leads to enhanced efficacy of immune stimulatory gene therapy in diffuse hemispheric gliomas","author":"Garcia-Fabiani","year":"2025","journal-title":"bioRxiv"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301966","article-title":"Characterization of distinct immunophenotypes across pediatric brain tumor types","volume":"191","author":"Griesinger","year":"2013","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab155","article-title":"Tumour immune landscape of paediatric high-grade gliomas","volume":"144","author":"Ross","year":"2021","journal-title":"Brain"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30724","article-title":"Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues","volume":"123","author":"Majzner","year":"2017","journal-title":"Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13649","article-title":"Local and systemic effects of IDH mutations on primary glioma patients","volume":"169","author":"Tang","year":"2023","journal-title":"Immunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai8478","article-title":"Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq","volume":"355","author":"Venteicher","year":"2017","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/gad.294991.116","article-title":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","volume":"31","author":"Amankulor","year":"2017","journal-title":"Genes Dev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","article-title":"Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma","volume":"6","author":"Lin","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108917","article-title":"Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality","volume":"34","author":"Dang","year":"2021","journal-title":"Cell Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1398877","article-title":"Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma","volume":"7","author":"Vermeulen","year":"2018","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24951","article-title":"PD-L1 expression in medulloblastoma: an evaluation by subgroup","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1144","article-title":"Tumor-associated macrophages in SHH subgroup of medulloblastomas","volume":"21","author":"Margol","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1462430","article-title":"Subgroup-specific immune and stromal microenvironment in medulloblastoma","volume":"7","author":"Bockmayr","year":"2018","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nm1707","article-title":"Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells","volume":"14","author":"Ding","year":"2008","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.03.002","article-title":"Medulloblastoma genotype dictates blood brain barrier phenotype","volume":"29","author":"Phoenix","year":"2016","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRP\u03b1 anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for Malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1038\/s41467-020-18070-y","article-title":"Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity","volume":"11","author":"Grabovska","year":"2020","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad031","article-title":"Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS Malignancies: safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908","volume":"25","author":"Dunkel","year":"2023","journal-title":"Neuro Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0411","article-title":"Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency","volume":"29","author":"Das","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2991-5","article-title":"Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience","volume":"140","author":"Kline","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"B78","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001339","article-title":"Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: a single institutional experience","volume":"41","author":"Gorsi","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0163","article-title":"Durable response to nivolumab in a pediatric patient with refractory glioblastoma and constitutional biallelic mismatch repair deficiency","volume":"23","author":"AlHarbi","year":"2018","journal-title":"Oncologist"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114034","article-title":"REVOLUMAB: a phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas","volume":"202","author":"Picca","year":"2024","journal-title":"Eur J Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab196.224","article-title":"CTIM-32. Immune checkpoint inhibitor nivolumab in people with recurrent select rare CNS cancers: results of interim analysis in a heavily pretreated cohort","volume":"23","author":"Penas-Prado","year":"2021"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae165.0337","article-title":"CTIM-03. Immune checkpoint inhibitor nivolumab in people with recurrent select rare CNS cancers: results of interim analysis in a non-heavily pretreated cohort","volume":"26","author":"Argao","year":"2024"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyy392","article-title":"Cytokine microdialysis for real-time immune monitoring in glioblastoma patients undergoing checkpoint blockade","volume":"84","author":"Lynes","year":"2019","journal-title":"Neurosurgery"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf064","article-title":"Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: results of the completed BrainChild02 phase 1 clinical trial","volume":"27","author":"Gust","year":"2025","journal-title":"Neuro Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001076","article-title":"Chimeric antigen receptor adoptive immunotherapy in central nervous system tumors: state of the art on clinical trials, challenges, and emerging strategies to addressing them","volume":"36","author":"Del Baldo","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1081\/cnv-120025091","article-title":"The first 1000 dendritic cell vaccinees","volume":"21","author":"Ridgway","year":"2003","journal-title":"Cancer Invest"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199609000-00003","article-title":"Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment","volume":"19","author":"Siesj\u00f6","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3171\/ped.2004.100.5.0492","article-title":"Transient local response and persistent tumor control in a child with recurrent Malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report","volume":"100","author":"De Vleeschouwer","year":"2004","journal-title":"J Neurosurg"},{"key":"B95","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9","article-title":"Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms","volume":"78","author":"Okada","year":"1998","journal-title":"Int J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000668","article-title":"Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer","volume":"6","author":"Caruso","year":"2004","journal-title":"Neuro Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22319","article-title":"Adjuvant dendritic cell-based tumour vaccination for children with Malignant brain tumours","volume":"54","author":"Ardon","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077613","article-title":"Adjuvant Wilms\u2019 tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I\/II clinical trial in Belgium","volume":"14","author":"Van Genechten","year":"2024","journal-title":"BMJ Open"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00127","article-title":"Immune response generated with the administration of autologous dendritic cells pulsed with an allogenic tumoral cell-lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma","volume":"8","author":"Benitez-Ribas","year":"2018","journal-title":"Front Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"iii306","DOI":"10.1093\/neuonc\/noaa222.136","article-title":"EPCT-13. CMV PP65 RNA-pulsed dendritic cell vaccines for pediatric glioblastoma and medulloblastoma: phase I trial results","volume":"22","author":"Landi","year":"2020"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2025.101183","article-title":"Whole-tissue and autologous dendritic cell vaccines in pediatric brain tumors: a focused review of current evidence and future directions","volume":"53","author":"Gianneschi","year":"2025","journal-title":"Semin Pediatr Neurol"},{"key":"B102","article-title":"Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas","volume":"33","author":"Lasky","year":"2013","journal-title":"Anticancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-4","article-title":"Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent Malignant brain tumors induces a CD4(+)IL17(+) response","volume":"2","author":"Olin","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.06.004","article-title":"Immunotherapy in atypical teratoid-rhabdoid tumors: data from a survey of the HGG-Immuno Group","volume":"18","author":"van Gool","year":"2016","journal-title":"Cytotherapy"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent Malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(23)00031-7","article-title":"Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial","volume":"7","author":"Thompson","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf079","article-title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-7567487\/v1","article-title":"Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205","author":"Wainwright","year":"2025","journal-title":"Res Sq"},{"key":"B114","doi-asserted-by":"publisher","first-page":"ii237","DOI":"10.1093\/neuonc\/noaa215.988","article-title":"LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA","volume":"22","author":"Reardon","year":"2022"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019307","article-title":"Epigenetic control of immunity","volume":"6","author":"Busslinger","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244149","article-title":"Progress toward epigenetic targeted therapies for childhood cancer","volume":"16","author":"Liapodimitri","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00277-005-0008-x","article-title":"Decitabine: a historical review of the development of an epigenetic drug","author":"de Vos","year":"2005","journal-title":"Ann Hematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B119","first-page":"16742","article-title":"Secura Bio, Inc.; Withdrawal of Approval of New Drug Application for FARYDAK (Panobinostat) Capsules, 10 Milligrams, 15 Milligrams, and 20 Milligrams","volume":"87","author":"Lipstein Fristedt","year":"2022"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0496","article-title":"Epigenetic regulation by histone methylation and histone variants","volume":"19","author":"Cheung","year":"2005","journal-title":"Mol Endocrinol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1035902","article-title":"Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein","volume":"16","author":"Kuzmichev","year":"2002","journal-title":"Genes Dev"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/35020506","article-title":"Regulation of chromatin structure by site-specific histone H3 methyltransferases","volume":"406","author":"Rea","year":"2000","journal-title":"Nature"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0017","article-title":"Simultaneous inhibition of LSD1 and TGF\u03b2 enables eradication of poorly immunogenic tumors with anti-PD-1 treatment","volume":"11","author":"Sheng","year":"2021","journal-title":"Cancer Discov"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa058","article-title":"Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma","volume":"22","author":"Bailey","year":"2020","journal-title":"Neuro Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03520-4","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"595","author":"Griffin","year":"2021","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0754","article-title":"The SETDB1-TRIM28 complex suppresses antitumor immunity","volume":"9","author":"Lin","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3523","article-title":"SETDB1 restrains endogenous retrovirus expression and antitumor immunity during radiotherapy","volume":"82","author":"Pan","year":"2022","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201612160","article-title":"Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia","volume":"216","author":"Cuellar","year":"2017","journal-title":"J Cell Biol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183745","article-title":"Activating antiviral immune responses potentiates immune checkpoint inhibition in glioblastoma models","volume":"135","author":"Seetharam","year":"2025","journal-title":"J Clin Invest"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1101\/gr.234229.118","article-title":"Switching roles for DNA and histone methylation depend on evolutionary ages of human endogenous retroviruses","volume":"28","author":"Ohtani","year":"2018","journal-title":"Genome Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0499-y","article-title":"Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression","volume":"25","author":"Segovia","year":"2019","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41420-020-00400-0","article-title":"Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis","volume":"7","author":"Ishiguro","year":"2021","journal-title":"Cell Death Discov"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s42003-024-07214-1","article-title":"Targeting heterochromatin eliminates chronic myelomonocytic leukemia Malignant stem cells through reactivation of retroelements and immune pathways","volume":"7","author":"Hidaoui","year":"2024","journal-title":"Commun Biol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf8627","article-title":"H3K9 dimethylation safeguards cancer cells against activation of the interferon pathway","volume":"8","author":"Hansen","year":"2022","journal-title":"Sci Adv"},{"key":"B138","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402201","article-title":"Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis","volume":"14","author":"Obeid","year":"2007","journal-title":"Cell Death Differ"},{"key":"B140","first-page":"65","article-title":"Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells","volume":"4","author":"Apetoh","year":"2007","journal-title":"Cancer Genomics Proteomics"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41467-017-02242-4","article-title":"Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors","volume":"9","author":"Kalin","year":"2018","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.190287","article-title":"CoREST complex inhibition alters RNA splicing to promote neoantigen expression and enhance tumor immunity","volume":"11","author":"Fisher","year":"2026","journal-title":"JCI Insight"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215489","article-title":"Inhibiting lysine demethylase 1A improves L1CAM-specific CAR T cell therapy by unleashing antigen-independent killing via the FAS-FASL axis","volume":"13","author":"Sulejmani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1037-z","article-title":"MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing","volume":"60","author":"Bao","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae023","article-title":"DNA methylation landscapes in DIPG reveal methylome variability that can be modified pharmacologically","volume":"6","author":"Tetens","year":"2024","journal-title":"Neuro-Oncol Adv"},{"key":"B148","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-025-02173-y","article-title":"Disordered DNA methylation leads to targetable transcriptional plasticity in ATRT","volume":"14","author":"Tetens","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2015.1017198","article-title":"Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts","volume":"10","author":"Srivastava","year":"2015","journal-title":"Epigenetics"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.4161\/epi.25500","article-title":"DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11","volume":"8","author":"James","year":"2013","journal-title":"Epigenetics"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1764-9","article-title":"Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1","volume":"35","author":"Krishnadas","year":"2014","journal-title":"Tumour Biol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac107","article-title":"Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma","volume":"24","author":"Ma","year":"2022","journal-title":"Neuro Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00262-008-0582-6","article-title":"Treatment of ovarian cancer cell lines with 5-aza-2\u2019-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules","volume":"58","author":"Adair","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf241","article-title":"Preclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergy","volume":"8","author":"Mishra","year":"2026","journal-title":"Neuro-Oncol Adv"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200766","article-title":"Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy","volume":"32","author":"Russo","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14191","article-title":"G9a promotes immune suppression by targeting the Fbxw7\/Notch pathway in glioma stem cells","volume":"29","author":"Cao","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"B158","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am J Transl Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B160","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12885-020-07008-8","article-title":"INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I\/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk Malignancies","volume":"20","author":"van Tilburg","year":"2020","journal-title":"BMC Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1126\/science.1242974","article-title":"Beyond stem cells: self-renewal of differentiated macrophages","volume":"342","author":"Sieweke","year":"2013","journal-title":"Science"},{"key":"B162","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2026.01.020","article-title":"Macrophages: Targets for next-generation cancer immunotherapy","volume":"44","author":"Sun","year":"2026","journal-title":"Cancer Cell"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.ccell.2024.11.002","article-title":"Myeloid effector cells in cancer","volume":"42","author":"Schol","year":"2024","journal-title":"Cancer Cell"},{"key":"B164","doi-asserted-by":"publisher","first-page":"36804","DOI":"10.1038\/s41598-025-20749-5","article-title":"Histone deacetylase inhibitors sensitize glioblastoma models to temozolomide and reprogram immunosuppressive myeloid cells","volume":"15","author":"Tehrani","year":"2025","journal-title":"Sci Rep"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf135","article-title":"Epigenetic and metabolic regulation of macrophage responsiveness and memory","volume":"214","author":"Daskalaki","year":"2025","journal-title":"J Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104779","article-title":"Pharmacological inhibition of DNMT1 restores macrophage autophagy and M2 polarization in Western diet-induced nonalcoholic fatty liver disease","volume":"299","author":"Pant","year":"2023","journal-title":"J Biol Chem"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104193","article-title":"Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections","volume":"29","author":"Bhat","year":"2024","journal-title":"Drug Discov Today"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238943","article-title":"Inhibition of HDAC enzymes contributes to differential expression of pro-inflammatory proteins in the TLR-4 signaling cascade","volume":"21","author":"Weiss","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01609","article-title":"Inhibiting histone deacetylases in human macrophages promotes glycolysis, IL-1\u03b2, and T helper cell responses to mycobacterium tuberculosis","volume":"11","author":"Cox","year":"2020","journal-title":"Front Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/ni1428","article-title":"Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice","volume":"8","author":"Kim","year":"2007","journal-title":"Nat Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.007","article-title":"The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation","volume":"42","author":"DuPage","year":"2015","journal-title":"Immunity"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99760","article-title":"Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy","volume":"128","author":"Goswami","year":"2018","journal-title":"J Clin Invest"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep"},{"key":"B175","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"B176","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1093\/neuonc\/noae064.168","article-title":"TRLS-15. \u201cTAZNI\u201d: A PHASE I\/II COMBINATION TRIAL OF TAZEMETOSTAT WITH NIVOLUMAB AND IPILIMUMAB FOR CHILDREN WITH INI1-NEGATIVE OR SMARCA4-DEFICIENT TUMORS (NCT05407441)","volume":"26","author":"Yi","year":"2024","journal-title":"Neuro Oncol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.969660","article-title":"Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"13","author":"Qu","year":"2022","journal-title":"Front Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010294","article-title":"T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy","volume":"13","author":"Bear","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0073","article-title":"Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70284","article-title":"G9a epigenetically suppresses CXCL10 expression and inhibits anti-tumor immunity in hepatocellular carcinoma","volume":"158","author":"Chai","year":"2026","journal-title":"Int J Cancer"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03268-5","article-title":"Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma","volume":"44","author":"Oyon","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001335","article-title":"Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma","volume":"9","author":"Seier","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0743","article-title":"Dual G9A\/EZH2 inhibition stimulates antitumor immune response in ovarian high-grade serous carcinoma","volume":"21","author":"Spiliopoulou","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073917","article-title":"Targeting group 3 medulloblastoma by the anti-PRUNE-1 and anti-LSD1\/KDM1A epigenetic molecules","volume":"25","author":"Bibb\u00f2","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B188","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1038\/s41467-022-31504-z","article-title":"CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas","volume":"13","author":"Niborski","year":"2022","journal-title":"Nat Commun"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.014","article-title":"Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"139","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.018","article-title":"Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE","volume":"146","author":"Pearson","year":"2021","journal-title":"Eur J Cancer"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab115","article-title":"BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma","volume":"23","author":"Gusyatiner","year":"2021","journal-title":"Neuro Oncol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr1557","article-title":"Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma","volume":"18","author":"Holliday","year":"2026","journal-title":"Sci Transl Med"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2018.07.008","article-title":"Structure and function of the histone chaperone FACT - Resolving FACTual issues","volume":"1861","author":"Gurova","year":"2018","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"B197","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s10020-025-01264-9","article-title":"Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma","volume":"31","author":"Kumari","year":"2025","journal-title":"Mol Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1021\/jm401480r","article-title":"Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP","volume":"56","author":"Liu","year":"2013","journal-title":"J Med Chem"},{"key":"B199","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1038\/s41467-025-59128-z","article-title":"Development of a brain-penetrant G9a methylase inhibitor to target Alzheimer\u2019s disease-associated proteopathology","volume":"16","author":"Xie","year":"2025","journal-title":"Nat Commun"},{"key":"B200","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2\u2019-deoxycytidine in rabbits and dogs","volume":"43","author":"Chabot","year":"1983","journal-title":"Cancer Res"},{"key":"B201","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noy084","article-title":"Immunotherapy in CNS cancers: the role of immune cell trafficking","volume":"21","author":"Ratnam","year":"2019","journal-title":"Neuro Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1716-2","article-title":"Current challenges in designing GBM trials for immunotherapy","volume":"123","author":"Weathers","year":"2015","journal-title":"J Neuro-Oncol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B206","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1600-065X.2006.00441.x","article-title":"CNS immune privilege: hiding in plain sight","volume":"213","author":"Carson","year":"2006","journal-title":"Immunol Rev"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.08.006","article-title":"Revisiting the mechanisms of CNS immune privilege","volume":"36","author":"Louveau","year":"2015","journal-title":"Trends Immunol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01175-0","article-title":"Redefining CNS immune privilege","volume":"25","author":"Smyth","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41911","article-title":"Trafficking of immune cells in the central nervous system","volume":"120","author":"Wilson","year":"2010","journal-title":"J Clin Invest"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2008.07.010","article-title":"Chromatin structure influences the sensitivity of DNA to gamma-radiation","volume":"1783","author":"Falk","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0050","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine","volume":"11","author":"Dote","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2017.1287454","article-title":"Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications","volume":"93","author":"Miousse","year":"2017","journal-title":"Int J Radiat Biol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.2307\/3577319","article-title":"The effect of gamma radiation on DNA methylation","volume":"117","author":"Kalinich","year":"1989","journal-title":"Radiat Res"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.8.2957","article-title":"Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2019-deoxycytidine (decitabine) treatment","volume":"100","author":"Daskalakis","year":"2002","journal-title":"Blood"},{"key":"B215","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","author":"Baylin","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"B216","unstructured":"DACOGEN\u00ae (decitabine) for injection, for intravenous use"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(78)90160-0","article-title":"Distribution of valproate across the interface between blood and cerebrospinal fluid","volume":"17","author":"Frey","year":"1978","journal-title":"Neuropharmacology"},{"key":"B220","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B221","first-page":"12","article-title":"NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma","volume":"13","author":"von Boehmer","year":"2013","journal-title":"Cancer Immun"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006930","article-title":"Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade","volume":"11","author":"Frankiw","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7326","article-title":"Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy","volume":"7","author":"Srivastava","year":"2016","journal-title":"Oncotarget"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1857121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:33Z","timestamp":1784867013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1857121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":223,"alternative-id":["10.3389\/fonc.2026.1857121"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1857121","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1857121"}}